ABSTRACT
Abstract: Amyloidosis cutis dyschromica is a rare type of primary cutaneous amyloidosis characterized by reticulate hyper-pigmentation with discrete hypopigmented macules. Up to date, about 50 cases of amyloidosis cutis dyschromica have been reported and the majority are familial cases of Asian ethnicity. Various diseases, particularly autoimmune diseases such as systemic sclerosis and systemic lupus erythematosus, have been associated with amyloidosis cutis dyschromica. Herein, we report a case of amyloidosis cutis dyschromica accompanying familial Mediterranean fever with a delayed diagnosis of 40 years. To the best of our knowledge, this is the first report of the association of amyloidosis cutis dyschromica and familial mediterranean fever.
Subject(s)
Humans , Female , Middle Aged , Familial Mediterranean Fever/complications , Skin Diseases, Genetic/complications , Skin Diseases, Genetic/pathology , Amyloidosis, Familial/complications , Amyloidosis, Familial/pathology , Biopsy , Hyperpigmentation/pathology , Dermis/pathologyABSTRACT
OBJECTIVE: This study evaluated the effects of sibutramine on intraocular pressure (IOP) and body-mass index (BMI). METHODS: Thirty obese females (body-mass index>30 kg/m2) treated with sibustramine (10 mg/day) plus plus diet restriction for 3 months were included in the study. IOP, BMI, and blood biochemical parameters were measured at the beginning and end of the treatment. Results were evaluated statistically by paired t-test, analysis of variance, and least-significant difference test. RESULTS: A statistically significant decrease was observed in the mean body-mas index (p<0.001) ans serum triglyceride (p<0.001), while a statistically significant increase was observed in IOP (p=0.54). CONCLUSION: While sibustramine provided an effective means for weight loss, it caused a slight increase in IOP, although this was not statistically significant. Nevertheless, it is prudent to monitor IOP in selected obese patients treated with sibustramine.